Compare Lululemon Athletica Inc (LULU) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Medpace Holdings Inc — how do they compare? Lululemon Athletica Inc trades at $94.41 (market cap $10.27B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and Medpace Holdings Inc for 14 Days on average.
| LULU | MEDP | |
|---|---|---|
Market Cap | $10.27B | $16.82B |
Volume | 4,392,324 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $630.19 |
52-Week Low | $91.88 | $393.42 |
Typical Hold Time | 105 Days | 14 Days |
Enterprise Value | $11.02B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.21, down 54% year-to-date and near its 52-week low. Despite strong profitability with a 56.11% gross margin and 30.9% ROE, recent revenue declines and a bearish technical signal have pressured shares. Multiple law firms are investigating potential securities fraud following the stock's sharp drop, while earnings have consistently beaten expectations.
The outlook remains challenged by growth concerns and governance scrutiny, though a low P/E of 7.63 offers valuation support. Risks include competitive pressures and ongoing legal probes, but analyst consensus targets $97.67, suggesting moderate upside if execution improves.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
